[PDF][PDF] Research progress of TCM combined with EGFR-TKI drugs in the treatment of advanced non-small cell lung cancer
WT Guo, WZ Shou - Adv Clin Exp Med, 2020 - pdf.hanspub.org
In recent years, lung cancer incidence and mortality of cancer at first, but the vast majority of
patients in the first option is already late, loses the chance of radical surgery treatment, …
patients in the first option is already late, loses the chance of radical surgery treatment, …
… plus Fuzheng Kang'ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a randomized …
X Yang, X Chai, W Wu, S Long, H Deng, Z Pan… - Chinese journal of …, 2018 - Springer
… Randomized phase Ⅱ study of erlotinib plus tivantinib versus erlotinib plus placebo in
previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3015. …
previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3015. …
[PDF][PDF] EGFR-TKI 有效肺癌经“药物间歇” 后再获TKI 敏感
陆舜， 李子明， 杨露璐 - 循证医学, 2013 - jebm.cn
… of a phase Ⅱ trial in patients with advaned non-smallcell lung … Randomized phase Ⅱ study
of dacomitinib (PF-00299804), … versus Erlotinib in patients with advanced nonsmall-cell lung …
of dacomitinib (PF-00299804), … versus Erlotinib in patients with advanced nonsmall-cell lung …
[PDF][PDF] EGFR 的突变异质性及在肺腺癌中对EGFR-TKI 反应的不一致性
周彩存， 林欢 - 循证医学, 2013 - jebm.cn
… of a phase Ⅱ trial in patients with advaned non-smallcell lung … Randomized phase Ⅱ study
of dacomitinib (PF-00299804), … versus Erlotinib in patients with advanced nonsmall-cell lung …
of dacomitinib (PF-00299804), … versus Erlotinib in patients with advanced nonsmall-cell lung …
表皮生长因子受体酪氨酸激酶抑制剂在野生型进展期非小细胞肺癌治疗中的地位
辛田， 马锐 - 循证医学, 2014 - jebm.cn
… Multi-institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients
with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21(12):2237-2246. Kris MG, …
with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21(12):2237-2246. Kris MG, …
DC-CIK 细胞联合EGFR-TKI 治疗35 例老年晚期EGFR 突变肺癌的效果
王福立， 孙银萍， 秦杰， 荣建胜 - 山东大学学报(医学版), 2022 - yxbwk.njournal.sdu.edu.cn
… or older)advanced non-small cell lung cancer patients with active epidermal growth factor
receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study[J]. …
receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study[J]. …
[HTML][HTML] 新辅助化疗, 靶向治疗联合手术治疗临床Ⅲ 期EGFR 阳性肺腺癌
赵晨， 张辉， 刘冬， 张淼， 武文斌… - 中华胸部外科电子 …, 2021 - zhxbwkdzzz.cma-cmc.com.cn
… Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell
lung cancer based on epidermal growth factor receptor mutation status[J]. J Hematol Oncol, …
lung cancer based on epidermal growth factor receptor mutation status[J]. J Hematol Oncol, …
[HTML][HTML] 吉非替尼联合化疗治疗50 例晚期非小细胞肺癌患者的疗效
王建丽， 王筱静， 孙玉莲， 胡晓乐… - 山东大学学报(医学 …, 2022 - yxbwk.njournal.sdu.edu.cn
… before and after Gefitinib therapy on patients with advanced non-small cell lung cancer[J]. …
analysis of gefitinib versus pemetrexed combined with cisplatin in patients with stage Ⅱ-Ⅲ A …
analysis of gefitinib versus pemetrexed combined with cisplatin in patients with stage Ⅱ-Ⅲ A …
[PDF][PDF] 晚期非小细胞肺癌的二线治疗进展
张力 - 2008 - scholar.archive.org
… Vinflunine--an active chemotherapy for treatment of advanced non-small-cell lung cancer
previously treated with a platinum-based regimen: results of a phase II study.Br J Cancer. 2006…
previously treated with a platinum-based regimen: results of a phase II study.Br J Cancer. 2006…